Details:
McMaster University researchers using MediPharm Labs’ CBD50 formula and CBD:THC 10:2 formulation, which has the same as MediPharm Labs’ CBD25, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-controlled trial.
Lead Product(s): Cannabidiol
Therapeutic Area: Sleep Product Name: CBD50
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: McMaster University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
Three initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD (cannabidiol) drug candidates for multiple indications including Pain, Insomnia associated with Major Depression, and Uremic Pruritus.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: McMaster University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 21, 2021